245 related articles for article (PubMed ID: 12648234)
1. High frequency of ultraviolet mutations at the INK4a-ARF locus in squamous cell carcinomas from psoralen-plus-ultraviolet-A-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Cerroni L; Kerl H; Wolf P
J Invest Dermatol; 2003 Apr; 120(4):676-82. PubMed ID: 12648234
[TBL] [Abstract][Full Text] [Related]
2. Ultraviolet exposure as the main initiator of p53 mutations in basal cell carcinomas from psoralen and ultraviolet A-treated patients with psoriasis.
Seidl H; Kreimer-Erlacher H; Bäck B; Soyer HP; Höfler G; Kerl H; Wolf P
J Invest Dermatol; 2001 Aug; 117(2):365-70. PubMed ID: 11511317
[TBL] [Abstract][Full Text] [Related]
3. The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.
Wolf P; Kreimer-Erlacher H; Seidl H; Bäck B; Soyer HP; Kerl H
J Invest Dermatol; 2004 Jan; 122(1):190-200. PubMed ID: 14962108
[TBL] [Abstract][Full Text] [Related]
4. High mutation frequency at Ha-ras exons 1-4 in squamous cell carcinomas from PUVA-treated psoriasis patients.
Kreimer-Erlacher H; Seidl H; Bäck B; Kerl H; Wolf P
Photochem Photobiol; 2001 Aug; 74(2):323-30. PubMed ID: 11547572
[TBL] [Abstract][Full Text] [Related]
5. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA).
Nataraj AJ; Wolf P; Cerroni L; Ananthaswamy HN
J Invest Dermatol; 1997 Aug; 109(2):238-43. PubMed ID: 9242514
[TBL] [Abstract][Full Text] [Related]
6. INK4a-ARF mutations in skin carcinomas from UV irradiated hairless mice.
Soufir N; Queille S; Mollier K; Roux E; Sarasin A; de Gruijl FR; Fourtanier AM; Daya-Grosjean L; Basset-Seguin N
Mol Carcinog; 2004 Apr; 39(4):195-8. PubMed ID: 15057871
[TBL] [Abstract][Full Text] [Related]
7. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
8. Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient.
Soufir N; Ribojad M; Magnaldo T; Thibaudeau O; Delestaing G; Daya-Grosjean L; Rivet J; Sarasin A; Basset-Seguin N
J Invest Dermatol; 2002 Dec; 119(6):1355-60. PubMed ID: 12485439
[TBL] [Abstract][Full Text] [Related]
9. Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients.
Soufir N; Daya-Grosjean L; de La Salmonière P ; Moles JP; Dubertret L; Sarasin A; Basset-Seguin N
J Natl Cancer Inst; 2000 Nov; 92(22):1841-7. PubMed ID: 11078762
[TBL] [Abstract][Full Text] [Related]
10. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
11. An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA.
Wang XM; McNiff JM; Klump V; Asgari M; Gasparro FP
Photochem Photobiol; 1997 Aug; 66(2):294-9. PubMed ID: 9277151
[TBL] [Abstract][Full Text] [Related]
12. Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck.
Poi MJ; Yen T; Li J; Song H; Lang JC; Schuller DE; Pearl DK; Casto BC; Tsai MD; Weghorst CM
Mol Carcinog; 2001 Jan; 30(1):26-36. PubMed ID: 11255261
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.
Nindl I; Gottschling M; Krawtchenko N; Lehmann MD; Röwert-Huber J; Eberle J; Stockfleth E; Forschner T
Br J Dermatol; 2007 May; 156 Suppl 3():34-9. PubMed ID: 17488404
[TBL] [Abstract][Full Text] [Related]
14. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy).
Lambertini L; Surin K; Ton TV; Clayton N; Dunnick JK; Kim Y; Hong HH; Devereux TR; Sills RC
Toxicol Pathol; 2005; 33(2):292-9. PubMed ID: 15902973
[TBL] [Abstract][Full Text] [Related]
16. Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks.
Gasparro FP; Liao B; Foley PJ; Wang XM; McNiff JM
Environ Mol Mutagen; 1998; 31(2):105-12. PubMed ID: 9544188
[TBL] [Abstract][Full Text] [Related]
17. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis.
Stern RS; Bagheri S; Nichols K;
J Am Acad Dermatol; 2002 Jul; 47(1):33-9. PubMed ID: 12077578
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients.
Katz KA; Marcil I; Stern RS
J Invest Dermatol; 2002 Jun; 118(6):1038-43. PubMed ID: 12060400
[TBL] [Abstract][Full Text] [Related]
19. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study.
Stern RS; Liebman EJ; Väkevä L
J Natl Cancer Inst; 1998 Sep; 90(17):1278-84. PubMed ID: 9731734
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization.
Stern RS; Bolshakov S; Nataraj AJ; Ananthaswamy HN
J Invest Dermatol; 2002 Aug; 119(2):522-6. PubMed ID: 12190879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
